GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Cash Flow from Financing

LSB (LakeShore Biopharma Co) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, LakeShore Biopharma Co paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, LakeShore Biopharma Co spent $0.00 Mil on financial activities for the three months ended in Sep. 2023.


LakeShore Biopharma Co Cash Flow from Financing Historical Data

The historical data trend for LakeShore Biopharma Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Cash Flow from Financing Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Cash Flow from Financing
113.54 57.46 46.07 28.50

LakeShore Biopharma Co Quarterly Data
Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only - - - - -

LakeShore Biopharma Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

LakeShore Biopharma Co's Cash from Financing for the fiscal year that ended in Mar. 2024 is calculated as:

LakeShore Biopharma Co's Cash from Financing for the quarter that ended in Sep. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LakeShore Biopharma Co  (NAS:LSB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

LakeShore Biopharma Co's issuance of stock for the three months ended in Sep. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

LakeShore Biopharma Co's repurchase of stock for the three months ended in Sep. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

LakeShore Biopharma Co's net issuance of debt for the three months ended in Sep. 2023 was $0.00 Mil. LakeShore Biopharma Co received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

LakeShore Biopharma Co's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. LakeShore Biopharma Co paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

LakeShore Biopharma Co's cash flow for dividends for the three months ended in Sep. 2023 was $0.00 Mil. LakeShore Biopharma Co received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

LakeShore Biopharma Co's other financing for the three months ended in Sep. 2023 was $0.00 Mil. LakeShore Biopharma Co received $0.00 Mil on other financial activities.


LakeShore Biopharma Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.